Sihuan Pharmaceutical Holdings Group Ltd.
SEHK:460 Rapporto sulle azioni
Sihuan Pharmaceutical Holdings Group Performance dei guadagni passati
Il passato criteri di controllo 0/6 Sihuan Pharmaceutical Holdings Group ha registrato una crescita degli utili a un tasso medio annuo di 13%, mentre il settore Pharmaceuticals ha registrato utili in crescita a un tasso medio annuo di 5.7%. I ricavi sono stati in diminuzione a un tasso medio annuo di 9.9%.
Informazioni chiave
13.0%
Tasso di crescita degli utili
12.6%
Tasso di crescita dell'EPS
Pharmaceuticals Crescita del settore 5.6% Tasso di crescita dei ricavi -9.9% Rendimento del capitale proprio -4.1% Margine netto -2.2% Ultimo aggiornamento sui guadagni 30 Jun 2024
Aggiornamenti sulle prestazioni recenti
First half 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.005 loss in 1H 2023) Sep 02
Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2024 Results on Aug 30, 2024 Aug 20
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 28
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 29
First half 2023 earnings released: CN¥0.005 loss per share (vs CN¥0.004 profit in 1H 2022) Aug 31
Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2023 Results on Aug 29, 2023 Aug 18
Mostra tutti gli aggiornamenti
What Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 25% Share Price Gain Is Not Telling You Oct 02
Is Sihuan Pharmaceutical Holdings Group (HKG:460) Using Too Much Debt? Sep 30
Upcoming dividend of HK$0.021 per share Sep 20
First half 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.005 loss in 1H 2023) Sep 02
Sihuan Pharmaceutical Holdings Group Ltd. Announces Interim Ordinary Cash Dividend for the Six Months Ended June 30, 2024, Payable on 10 October 2024 Aug 30
Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2024 Results on Aug 30, 2024 Aug 20
Sihuan Pharmaceutical Holdings Group Ltd.'s Honghe Pharmaceutical Co., Ltd. Obtains Drug Registration Approval from National Medical Products Administration Jun 26
New major risk - Revenue and earnings growth Jun 14
Sihuan Pharmaceutical Holdings Group Ltd. Announces Rivaroxaban Tablets (Strength: 2.5Mg) Obtained Drug Registration Approval from NMPA Jun 13
Here's Why It's Unlikely That Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO Will See A Pay Rise This Year May 31
Investors Still Waiting For A Pull Back In Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) May 27
Now 21% undervalued after recent price drop May 24
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 28
Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, Jun 07, 2024 Mar 29
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 29
Sihuan Pharmaceutical Holdings Group Ltd. Receives Registration Approval from National Medical Products Administration for Proline Janagliflozin Tablets Jan 23
Now 20% undervalued after recent price drop Jan 17
Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration of the People's Republic of China for the Treatment of Diabetes Jan 08
A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Dec 05
Health Check: How Prudently Does Sihuan Pharmaceutical Holdings Group (HKG:460) Use Debt? Oct 31
National Medical Products Administration Approves IND Application of Insulin Degludec and Liraglutide Injection, Developed by Huisheng Biopharmaceutical Oct 26
First half 2023 earnings released: CN¥0.005 loss per share (vs CN¥0.004 profit in 1H 2022) Aug 31
Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Aug 19
Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2023 Results on Aug 29, 2023 Aug 18
Sihuan Pharmaceutical Holdings Group Ltd. Announces Huisheng Biopharmaceutical's Drug Semaglutide Injection Obtained Approval for Clinical Trial Jul 06
Sihuan Pharmaceutical Holdings Group Ltd. Announces Approval of Phase II Clinical Trial Application of Birociclib by the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China Jul 04
Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration Jun 02
Upcoming dividend of HK$0.037 per share at 9.7% yield May 30
Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Apr 21
Full year 2022 earnings released: CN¥0.21 loss per share (vs CN¥0.044 profit in FY 2021) Mar 26
Sihuan Pharmaceutical Holdings Group Ltd. Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022 Jan 21
Less than half of directors are independent Nov 16
Is Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Worth HK$0.8 Based On Its Intrinsic Value? Nov 03
Sihuan Pharmaceutical Holdings Group Ltd. Announces Management Changes Oct 15
Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet? Oct 11
Upcoming dividend of HK$0.037 per share Sep 23 Sihuan Pharmaceutical Holdings Group Ltd. Declares Special Cash Dividend for the Six Months Ended 30 June 2022, Payable on or Around 13 October 2022
First half 2022 earnings released: EPS: CN¥0.004 (vs CN¥0.065 in 1H 2021) Aug 31
Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2022 Results on Aug 30, 2022 Aug 19
Sihuan Pharmaceutical Holdings Group Ltd. Provides Earnings Guidance for the Six Months Ended 30 June 2022 Aug 17
Sihuan Pharmaceutical Holdings Group Ltd. Announces Acceptance of Application for Marketing of Xuanzhu Biopharm\U0027s Drug Fulvestrant Injection by Nmpa of China Jul 28
Is There An Opportunity With Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 34% Undervaluation? Jun 21
Upcoming dividend of HK$0.13 per share May 19
Investor sentiment deteriorated over the past week May 06
Less than half of directors are independent Apr 27
Sihuan Pharmaceutical Obtains Class III Medical Device Registration Certificate from NMPA for Exclusively Distributed Hyaluronic Acid Persnica Apr 19
Now 20% undervalued Apr 07
Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, May 24, 2022 Mar 31
Full year 2021 earnings: EPS and revenues miss analyst expectations Mar 30 Sihuan Pharmaceutical Holdings Group Ltd. Announces Ordinary Final Cash Dividend for the Year Ended December 31, 2021, Payable on June 14, 2022
Investor sentiment deteriorated over the past week Mar 15
Now 25% undervalued after recent price drop Mar 14
Sihuan Pharmaceutical Holdings Group Ltd. Announces First Class I Macromolecule Innovative Drug Her2 Bispecific Antibody Xzp-Km257 Was Approves for Clinical Trails Mar 10
Estimating The Intrinsic Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Mar 09
Investor sentiment improved over the past week Feb 15
National Medical Products Administration Accepts Biologics License Application of Insulin Aspart Injection, Insulin Aspart 30 Injection and Insulin Aspart 50 Injection of Jilin Huisheng Biopharmaceutical Co., Ltd Jan 28
Now 22% undervalued after recent price drop Jan 25 Sihuan Pharmaceutical Holdings Group Ltd. Announces Medical Device Registration Certificate Obtained for Medical Skin Care Gel and Repair Gel
Sihuan Pharmaceutical Holdings Group Ltd. Announces Fondaparinux Sodium Injection Obtained Manufacture Approval Dec 22
A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Nov 28
Investor sentiment deteriorated over the past week Sep 27
Sihuan Pharmaceutical Holdings Group (HKG:460) Seems To Use Debt Rather Sparingly Sep 26
First half 2021 earnings released: EPS CN¥0.065 (vs CN¥0.018 in 1H 2020) Sep 03
Non-Executive Director Jin-ha Kim has left the company Aug 07
Investor sentiment deteriorated over the past week Jul 26
Consensus forecasts updated Jul 10
Investor sentiment deteriorated over the past week Jul 08
Upcoming dividend of HK$0.016 per share Jun 29
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO For Now Jun 22
Sihuan Pharmaceutical Holdings Group Ltd. Announces Obtains Drug Registration Approval in Relation to Caspofungin Acetate for Injection Jun 17
Sihuan Pharmaceutical Holdings Group Ltd. Recommends Final Cash Dividend for the Year Ended December 31, 2020, Payable on or Around July 15, 2021 May 29
Investor sentiment improved over the past week May 27
How Does Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Fare As A Dividend Stock? May 11
Investor sentiment improved over the past week Apr 15
Sihuan Pharmaceutical Holdings Group's (HKG:460) Shareholders May Want To Dig Deeper Than Statutory Profit Mar 30
Sihuan Pharmaceutical Holdings Group Ltd. Recommends Two Special Cash Dividends Mar 25
Full year 2020 earnings released: EPS CN¥0.054 (vs CN¥0.29 loss in FY 2019) Mar 24
Sihuan Pharmaceutical Holdings Group Ltd. to Report Fiscal Year 2020 Results on Mar 23, 2021 Mar 12
How Much Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Do Insiders Own? Mar 07
New 90-day high: HK$2.75 Feb 22
Sihuan Pharmaceutical Holdings Group Ltd. Announces Octreotide Acetate Injection (1Ml: 0.05Mg and 1Ml: 0.1Mg) of the Group has Obtained the Notice of Approval of Supplemental Applications on Pharmaceutical Products Issued by the National Medical Products Administration of the People's Republic of China Feb 09
Should You Buy Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) For Its Dividend? Feb 07
Sihuan Pharmaceutical Holdings Group Ltd. Announces Selection of its Pantoprazole Sodium Injection (Panzuoer® 40mg per unit) and Ibuprofen Injection (Falanfen® 4ml: 0.4g, Tenaan® 8ml: 0.8g) in the Fourth Batch of National Drug Centralized Procurement Feb 05 Sihuan Pharmaceutical Holdings Group Ltd. Announces Cinepazide Maleate Injection Obtain Approval from the National Medical Products Administration
New 90-day high: HK$1.32 Jan 20
Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Jan 11
Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet? Dec 21
Why Sihuan Pharmaceutical Holdings Group's (HKG:460) CEO Pay Matters Dec 07
Upcoming Dividend of HK$0.035 Per Share Sep 22
Sihuan Pharmaceutical Holdings Group Ltd.(SEHK:460) dropped from FTSE All-World Index (USD) Sep 21
First half earnings released Sep 14
Deputy General Manager recently bought HK$19m worth of stock Sep 03
Earnings released Aug 26
New 90-day high - HK$1.03 Aug 21
Ripartizione dei ricavi e delle spese
Come Sihuan Pharmaceutical Holdings Group guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate SEHK:460 Ricavi, spese e utili (CNY Millions ) Data Ricavi Guadagni Spese G+A Spese di R&S 30 Jun 24 1,755 -38 940 479 31 Mar 24 1,808 -46 926 528 31 Dec 23 1,861 -54 911 578 30 Jun 23 1,773 -2,041 898 773 31 Mar 23 1,977 -1,996 961 855 31 Dec 22 2,181 -1,951 1,023 937 30 Jun 22 2,595 -144 1,139 992 31 Mar 22 2,817 141 1,134 930 31 Dec 21 3,038 427 1,129 868 30 Sep 21 3,304 681 1,102 815 30 Jun 21 3,317 945 1,049 762 31 Mar 21 2,891 727 954 746 31 Dec 20 2,464 508 859 729 30 Sep 20 2,370 -14 792 698 30 Jun 20 2,275 -537 725 666 31 Mar 20 2,577 -1,623 721 633 31 Dec 19 2,878 -2,709 717 599 30 Sep 19 3,088 -1,927 722 566 30 Jun 19 3,297 -1,144 727 534 31 Mar 19 3,107 238 697 507 31 Dec 18 2,917 1,620 667 480 30 Sep 18 2,751 1,496 580 482 30 Jun 18 2,584 1,372 494 484 31 Mar 18 2,665 1,411 523 394 31 Dec 17 2,746 1,449 553 304 30 Sep 17 2,992 1,632 653 152 30 Jun 17 3,238 1,815 754 0 31 Mar 17 3,212 1,761 720 0 31 Dec 16 3,186 1,708 686 0 30 Sep 16 2,984 1,528 627 0 30 Jun 16 2,781 1,347 568 0 31 Mar 16 2,974 1,705 590 0 31 Dec 15 3,167 2,062 611 0 30 Sep 15 3,321 2,181 648 0 30 Jun 15 3,474 2,299 685 0 31 Mar 15 3,279 1,985 658 0 31 Dec 14 3,084 1,671 630 0 30 Sep 14 2,365 1,581 0 0 30 Jun 14 1,645 1,491 -631 0 31 Mar 14 2,116 1,388 -83 0 31 Dec 13 2,586 1,285 466 0
Guadagni di qualità: 460 al momento non è redditizia.
Margine di profitto in crescita: 460 al momento non è redditizia.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: 460 non è redditizia, ma ha ridotto le perdite negli ultimi 5 anni a un tasso pari a 13% all'anno.
Accelerare la crescita: Impossibile confrontare la crescita degli utili di 460 nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia
Guadagni vs Settore: 460 non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Pharmaceuticals ( 6.4% ).
Rendimento del capitale proprio
ROE elevato: 460 ha un Return on Equity negativo ( -4.06% ), in quanto al momento non è redditizio.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
